P. Nadler

发表

In Vivo Administration of Tumor Necrosis Factor-α is Associated with Antiviral Activity in Human Peripheral Mononuclear Cells

E. Schlick, R. Pollard, M. Jennings, 1991, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Efficacy of Sym 004 in PatientsWithMetastatic Colorectal CancerWith Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNAAnalyses A Phase 2 Randomized Clinical Trial

C. Nadal, R. Salazar, A. Bardelli, 2018 .

First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies

J. Berlin, A. Tolcher, A. Patnaik, 2022, Investigational New Drugs.

Human monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109): enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replication.

R. Pollard, M. Nokta, P. Nadler, 1991, Antiviral research.

Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody—treated liver transplant patients

Linda A Mccarthy, G. Mcmahon, P. Ehrlich, 1992, Hepatology.

A phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX.

H. Kouji, H. Lenz, E. Kwak, 2015 .

A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion

N. Coombe, T. Ahmed, A. Mittelman, 1992, Investigational New Drugs.

Clinical trials with human tumor necrosis factor: in vivo and in vitro effects on human mononuclear phagocyte function.

R. Bast, J. Weinberg, C. Greenberg, 1988, Cancer research.

Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection

D. Gibson, P. Nadler, H. Spiegel, 1984, Clinical pharmacology and therapeutics.

A phase I study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)

T. Blondal, A. Tolcher, F. Janku, 2019, Annals of Oncology.

T CELL RECOGNITION OF SYNGENEIC AND ALLOGENEIC H-2 DETERMINANTS

A. Singer, R. Hodes, K. Hathcock, 1979 .

Biologic response (antiviral) to recombinant human interferon alpha 2a as a aunction of dose and route of administration in healthy volunteers

F. Witter, D. Griffin, P. Lietman, 1987, Clinical pharmacology and therapeutics.

Therapeutic uses of macrophage colony-stimulating factor.

P. Nadler, 1990, Cancer investigation.

Therapy of genital herpes with topically applied interferon

L. Eron, P. Nadler, R. Scheer, 1987, Antimicrobial Agents and Chemotherapy.

The expression and functional involvement of nuclease‐specific idiotype on nuclease‐primed helper T cells

D. Sachs, R. Hodes, G. Miller, 1982, European journal of immunology.

Erlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel-Lindau disease: a case report

W. Kaelin, A. Shields, P. LoRusso, 2010, Journal of Neuro-Oncology.

T cell recognition in the mixed lymphocyte response. I. Non-T, radiation-resistant splenic adherent cells are the predominant stimulators in the murine mixed lymphocyte reaction.

R. Hodes, P. Nadler, G. Ahmann, 1979, Journal of immunology.

Induction of idiotype-bearing, nuclease-specific helper T cells by in vivo treatment with anti-idiotype

D. Sachs, Y. Asano, R. Hodes, 1981, The Journal of experimental medicine.

Safety and tolerability of two percent cyclosporine (Sandimmune) ophthalmic ointment in normal volunteers.

P. Nadler, M. Silverman, S. Solch, 1991, Journal of ocular pharmacology.

Anticorps monoclonaux humains contre le cytomegalovirus

P. Nadler, L. Östberg, 1994 .

The murine Kupffer cell. II. Accessory cell function in in vitro primary antibody responses, mitogen-induced proliferation, and stimulation of mixed lymphocyte responses.

R. Klingenstein, P. Nadler, L. K. Richman, 1980, Journal of immunology.

A randomized placebo-controlled trial of recombinant human interferon alpha 2a in patients with aids

R. Schooley, C. Crumpacker, H. Handsfield, 1988 .

Time course of interferon levels, antiviral state, 2',5'-oligoadenylate synthetase and side effects in healthy men.

F. Witter, D. Griffin, P. Lietman, 1987, Journal of interferon research.

T cell recognition in the mixed lymphocyte response. II. Ia-positive splenic adherent cells are required for non-I region-induced stimulation.

R. Hodes, P. Nadler, A. Birnkrant, 1981, Journal of immunology.

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial

C. Nadal, R. Salazar, A. Bardelli, 2018, JAMA oncology.

Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors

M. Hidalgo, A. Tolcher, M. Beeram, 2006, Clinical Cancer Research.

Modification of T cell antinuclease idiotype expression by in vivo administration of anti-idiotype

D. Sachs, R. Hodes, G. Miller, 1982, The Journal of experimental medicine.

NUCLEASE-SPECIFI C HELPER T CELLS BY IN VIVO TREATMENT WITH ANTI-IDIOTYPE

D. Sachs, Y. Asano, R. Hodes, 1981 .

P856 AVID200, first-in-class TGF-beta1 and beta3 selective inhibitor: results of a phase 1 monotherapy dose escalation study in solid tumors and evidence of target engagement in patients

M. O’Connor-McCourt, T. Yap, T. Gruosso, 2020, Journal of Immunotherapy for Cancer.

THU0329 SAFETY, TARGET ENGAGEMENT, AND INITIAL EFFICACY OF AVID200, A FIRST-IN-CLASS POTENT AND ISOFORM-SELECTIVE INHIBITOR OF TGF-BETA 1 AND 3, IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC): A PHASE 1 DOSE ESCALATION STUDY

A. Papazoglou, R. Domsic, R. Lafyatis, 2020 .

Genetic control of immune response to staphylococcal nuclease. XII: Analysis of nuclease antigenic determinants using anti-nuclease monoclonal antibodies

D. Sachs, G. Miller, C. Devaux, 1985, Molecular and Cellular Biochemistry.

High-resolution zone electrophoresis, combined with immunofixation, in the detection of an occult myeloma paraprotein.

D. Everett, C. Reichert, N. Papadopoulos, 1982, Clinical chemistry.

A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis.

M. Hirsch, L. Hubbard, A. Caliendo, 2004, Antiviral research.

Ontogeny of murine accessory cells: Ia antigen expression and accessory cell function in in vitro primary antibody responses.

R. Hodes, R. Klingenstein, P. Nadler, 1980, Journal of immunology.

Abstract A088: Novel anti-EGFR antibody-drug conjugate AVID100: A phase 2a trial in patients with EGFR-overexpressing advanced solid tumors

A. Tolcher, K. Papadopoulos, R. Lutz, 2019 .

Genetic control of antibody responses to TNP-nuclease in vitro.

D. Sachs, R. Hodes, P. Nadler, 1981, Journal of immunology.

Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial

A. Patnaik, D. V. Hoff, E. Rowinsky, 2007, Cancer Chemotherapy and Pharmacology.

1019O Phase I studies of Sym021, an anti-PD-1 antibody, alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)

A. Tolcher, F. Janku, T. T. Poulsen, 2020, Annals of Oncology.

Erlotinib + gemcitabine in patients with unresectable pancreatic carcinoma: Results from a phase IB trial.

A. Patnaik, E. Rowinsky, T. Dragovich, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of prednisone, aspirin, and acetaminophen on an in vivo biologic response to interferon in humans

F. Witter, P. Lietman, Craig R. Smith, 1988, Clinical pharmacology and therapeutics.